title: [Inhibitory effect of jianpi-jiedu prescription-contained serum on colorectal cancer SW48 cell proliferation by mTOR-P53-P21 signalling pathway].
abstract: To investigate the effect of jianpi-jiedu (JPJD) prescription-contained serum on colorectal cancer SW48 cell proliferation and the underlying mechanisms.  Methods: Crude extract from JPJD was made by water extract method and the main components of crude extract from JPJD were analyzed by ultra-performance liquid phase high resolution time of flight mass spectrometry (UPLC-Q-TOF/MS). The low, medium, and high-concentration of JPJD-contained serum were prepared by the serum pharmacological method. The effect of serum containing JPJD on SW48 cell proliferation was determined by MTT assay. The cell cycle was detected by flow cytometric method. The protein levels of mammalian target of rapamycin (mTOR), phospho-mTOR, P-P53, and -P21, and the mRNA level of mTOR were examined by Western blot and RT-PCR, respectively.  Results: Seven compounds including calycosin-7-glucoside, astragaloside, ginsenoside-Re, ginsenoside-Rb1, glycyrrhizinic acid, apigenin, atractylenolide-II were identified. MTT assays demonstrated that the SW48 cell proliferation was inhibited by medium and high concentration of JPJD-contained serum and the percentages of cells at G1 phase in SW48 cell cultured in the medium and high concentration of JPJD serum group were significantly higher than those in the control group (P<0.05). Meanwhile, the levels of mTOR mRNA and phospho-mTOR protein in the medium and high concentration of JPJD serum groups were substantially lower than those in the control group (P<0.05). Conversely, the expressions of phospho-P53 and P21 protein were significantly increased in the medium and high concentration of JPJD serum group compared with those in the control group.  Conclusion: JPJD prescription-contained serum can inhibit SW48 cell proliferation, which may be related to mTOR-P53-P21 signaling pathways.
authors.affiliation: Department of Integrated Chinese & Western Medicine, Second Xiangya Hospital, Central South University, Changsha 410011, China.
authors.forename: Fengxia
authors.initials: F
authors.lastname: Lin
authors.affiliation: Department of General Surgery, Second Xiangya Hospital, Central South University, Changsha 410011, China.
authors.forename: Sanlin
authors.initials: S
authors.lastname: Lei
authors.affiliation: Department of Oncology,  Second Xiangya Hospital, Central South University, Changsha 410011, China.
authors.forename: Jin'an
authors.initials: J
authors.lastname: Ma
authors.affiliation: Department of Integrated Chinese & Western Medicine, Second Xiangya Hospital, Central South University, Changsha 410011, China.
authors.forename: Li
authors.initials: L
authors.lastname: Shi
authors.affiliation: Department of Integrated Chinese & Western Medicine, Second Xiangya Hospital, Central South University, Changsha 410011, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Mao
authors.affiliation: Department of Integrated Chinese & Western Medicine, Second Xiangya Hospital, Central South University, Changsha 410011, China.
authors.forename: Shaofan
authors.initials: S
authors.lastname: Zhang
authors.affiliation: College of Pharmacy, Hunan University of Chinese Medicine, Changsha 410028, China.
authors.forename: Jianhua
authors.initials: J
authors.lastname: Huang
authors.affiliation: Department of Pharmacy, Second Xiangya Hospital, Central South University, Changsha 410011, China.
authors.forename: Xinyi
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Pharmacy, Second Xiangya Hospital, Central South University, Changsha 410011, China.
authors.forename: Dengfeng
authors.initials: D
authors.lastname: Ding
authors.affiliation: Department of Integrated Chinese & Western Medicine, Second Xiangya Hospital, Central South University, Changsha 410011, China.
authors.forename: Yingjin
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Integrated Chinese & Western Medicine, Second Xiangya Hospital, Central South University, Changsha 410011, China.
authors.forename: Sifang
authors.initials: S
authors.lastname: Zhang
mesh_terms: D000818:Animals; D047310:Apigenin; D015153:Blotting, Western; D002453:Cell Cycle; D002455:Cell Division; D049109:Cell Proliferation / Q000187:drug effects* / Q000235:genetics; D015179:Colorectal Neoplasms; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000187:drug effects; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D005434:Flow Cytometry; D036145:Ginsenosides; D019695:Glycyrrhizic Acid; D006801:Humans; D007783:Lactones; D010766:Phosphorylation / Q000235:genetics; D012333:RNA, Messenger; D012503:Saponins; D012717:Sesquiterpenes; D015398:Signal Transduction; D058570:TOR Serine-Threonine Kinases / Q000187:drug effects; D014315:Triterpenes; D016159:Tumor Suppressor Protein p53 / Q000187:drug effects
chemical_list: C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D004365:Drugs, Chinese Herbal; D036145:Ginsenosides; D007783:Lactones; D012333:RNA, Messenger; D012503:Saponins; D012717:Sesquiterpenes; D014315:Triterpenes; D016159:Tumor Suppressor Protein p53; C458582:atractylenolide II; C052064:astragaloside A; C049864:ginsenoside Re; D019695:Glycyrrhizic Acid; C442759:ginsenoside Rb1; D047310:Apigenin; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases